Citations

Clear

623 citation(s) found for "Torres, V".

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
Albain, Kathy S. , Yau, Christina , Petricoin, Emanuel F. , Wolf, Denise M. , Lang, Julie E. , Chien, A. Jo , Haddad, Tufia C. , Forero-Torres, Andres , Wallace, Anne M. , Kaplan, Henry G. , Euhus, David , Nanda, Rita , Clark, Amy S. , Godellas, Constantine , Tripathy, Debu , Lu, Janice , Yung, Rachel L. , Wulfkuhle, Julia , Krings, Gregor , Chen, Yunn‐Yi , Potter, David A. , Stringer-Reasor, Erica , Blair, Sarah L. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L. , Sanil, Ashish, Matthews, Jeffrey B. , Melisko, Michelle , Perlmutter, Jane , Symmans, W. Fraser , Veer, Laura J. van’t , Yee, Douglas , Berry, Donald A. , Haddad, Tufia C , Kaplan, Henry , Pusztai, Lajos , Euhus, David , Nanda, Rita , Elias, Anthony D , Clark, Amy S , Godellas, Constantine , Boughey, JC , Isaacs, Claudine , Tripathy, Debasish , Lu, Janice , Yung, Rachel L , Gallagher, Rosa I , Wulfkuhle, Julia D , Brown-Swigart, Lamorna , Krings, Gregor , Chen, Yunn Yi , Potter, David A , Stringer-Reasor, Erica , Blair, Sarah L , Asare, Smita M , Wilson, Amy , Hirst, Gillian L , Singhrao, Ruby , Buxton, Meredith , Clennell, Julia L , Berry, Scott , Asare, Adam L , Matthews, Jeffrey B , DeMichele, Angela , Hylton, Nola M. , Melisko, Michelle , Perlmutter, Jane , Rugo, Hope S , Symmans, W Fraser , Yee, Douglas , Berry, Donald , Esserman, Laura J , Pusztai, Lajos , Elias, Anthony , Boughey, Judy C. , Isaacs, Claudine , Gallagher, Rosa I. , Swigart, Lamorna Brown , Asare, Adam L. , DeMichele, Angela , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Clinical Cancer Research | December 18, 2023 | Volume: 30 | Issue: 4 | Pages: 729-740

10.1158/1078-0432.ccr-22-2256 | PMID 38109213 Get It

Abstract Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients and Methods: I-SPY2, a phase II neoadjuvant trial, adaptively randomizes patients with high-risk, early-stage breast cancer to one of several experimental therapies or control based on receptor subtypes as defined by hormone receptor (HR) and HER2 status and MammaPrint risk (MP1, MP2). The primary endpoint is pathologic complete response (pCR). A therapy “graduates” if/when it achieves 85% Bayesian probability of success in a phase III trial within a given subtype. Patients received weekly paclitaxel (plus trastuzumab if HER2-positive) without (control) or with weekly intravenous trebananib, followed by doxorubicin/cyclophosphamide and surgery. Pathway-specific biomarkers were assessed for response prediction. Results: There were 134 participants randomized to trebananib and 133 to control. Although trebananib did not graduate in any signature [phase III probabilities: Hazard ratio (HR)-negative (78%), HR-negative/HER2-positive (74%), HR-negative/HER2-negative (77%), and MP2 (79%)], it demonstrated high probability of superior pCR rates over control (92%–99%) among these subtypes. Trebananib improved 3-year event-free survival (HR 0.67), with no significant increase in adverse events. Activation levels of the Tie2 receptor and downstream signaling partners predicted trebananib response in HER2-positive disease; high expression of a CD8 T-cell gene signature predicted response in HR-negative/HER2-negative disease. Conclusions: The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
Crossmatch assays in transplantation: Physical or virtual?: A review
Rocha, Yermis , Jaramillo, Andrés , Neumann, Jorge , Hacke, Katrin , Palou, Eduard , Torres, Juan, Jaramillo, Andres , Torres, Juan Manuel

Mayo Clinic

Medicine | December 15, 2023 | Volume: 102 | Issue: 50 | Pages: e36527

10.1097/md.0000000000036527 | PMID 38115324 Get It

The value of the crossmatch test in assessing pretransplant immunological risk is vital for clinical decisions, ranging from the indication of the transplant to the guidance of induction protocols and treatment with immunosuppressants. The crossmatch tests in transplantation can be physical or virtual, each with its advantages and limitations. Currently, the virtual crossmatch stands out for its sensitivity and specificity compared to the physical tests. Additionally, the virtual crossmatch can be performed in less time, allowing for a reduction in cold ischemia time. It shows a good correlation with the results of physical tests and does not negatively impact graft survival. Proper communication between clinicians and the transplant immunology laboratory will lead to a deeper understanding of each patient’s immunological profile, better donor–recipient selection, and improved graft survival.
Acute postoperative and rehabilitation care managed in a virtual hybrid hospital‐at‐home after a total knee arthroplasty: A case report
Maita, Karla C. , Brand, Rusty C., Seep, Phillip J., Maniaci, Michael J. , Torres-Guzman, Ricardo A, Maniaci, Michael J , Paulson, Margaret R. , Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Forte, Antonio J.

Mayo Clinic

Clinical Case Reports | December 9, 2023 | Volume: 11 | Issue: 12 | Pages: No page available

10.1002/ccr3.8318 | PMID 38084352 Get It

Key Clinical Messages This case report demonstrates a virtual hybrid hospital‐at‐home program can provide inpatient‐level postoperative and rehabilitative care after total knee arthroplasty to a medically complex patient in the comfort of their own home. Abstract Advanced Care at Home combines virtual providers with in‐home care delivery. We report a case of virtual postoperative and rehabilitative care in a medically complex patient who underwent a total knee arthroplasty. This new model of care delivery allows effective patient‐provider communication and meets patient needs in the postoperative period.
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency through Adulthood (P5.159)
Lapalme‐Remis, Samuel , Lewis, Evan , Meulemeester, Christine De, Chakraborty, Pranesh, Gibson, K. Michael , Torres, Carlos , Guberman, A., Ali-Ridha, Andre, Parviz, Mahsa , Pearl, Phillip L. , Chakraborty, Pranesh K. , Salomons, Gajja S.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p5.159 Get It

Mesenchymal Stromal Cell Healing Outcomes in Clinical and Pre-Clinical Models to Treat Pressure Ulcers: A Systematic Review
Torres‐Guzman, Ricardo A. , Maita, Karla C. , Velasquez, Gioacchino D. De Sario , Borna, Sahar , Eldaly, Abdullah S. , Quiñones‐Hinojosa, Alfredo , Zubair, Abba C. , Ho, Olivia A. , Forte, Antonio J. , Maita, Karla , De Sario, Gioacchino D , Borna, Sahar , Zubair, Abba C , Forte, Antonio Jorge , Torres, Ricardo A , Ávila, Francisco R. , Garcia, John P.

Mayo Clinic

Journal of Clinical Medicine | December 7, 2023 | Volume: 12 | Issue: 24 | Pages: 7545

10.3390/jcm12247545 | PMID 38137625 Get It

Background: Despite numerous measures used to prevent pressure ulcers, their growing prevalence in recent years is expected to continue as the population ages. This review aims to report the outcomes of the regenerative potential of MSCs in treating pressure ulcers, assessing the effectiveness of MSCs in treating pressure ulcers. Methods: A computerized search for articles on animal models that use MSCs as primary therapy to treat pressure ulcers, published from conception to present, was conducted using PubMed, MEDLINE, Embase, and CINAHL. Our search yielded 52 articles, narrowed to 44 after excluding duplicates. Results: Out of 52 articles collected from four databases, 11 met the inclusion criteria. A total of 11 articles published between 2008 and 2020 met the inclusion criteria. Eight studies were observational descriptive papers in animal models, and three were prospective. Six studies used autologous MSCs, while five used allogenic MSCs. Three studies were conducted in humans, and the remaining eight were conducted in animals. The most common method of cell delivery was an intradermal injection in the margins of the ulcer. All studies reported positive results, including improved wound healing, reduced inflammation, and improved tissue regeneration. Conclusions: MSCs have shown promising results in treating pressure ulcers in animal and clinical trials. The combination of MSCs and scaffold materials has also been studied and found to be effective in wound healing. A standardized human wound model has been proposed further to investigate the efficacy of cell-based therapies for chronic wounds. However, more research is needed to determine the best quantity of cells to apply for pressure ulcers and to ensure the safety and efficacy of these treatments in clinical settings.
Natural history and treatment predictors in a cohort of IgM associated neuropathies (2514)
Torres, María, Thapa, Prabin , Triplett, James , Naddaf, Elie , Torres, Maria, Shelly, Shahar , Klein, Christopher J. , Mauermann, Michelle L.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2514 Get It

Measuring Ambulatory Neurologic Health Disparities with the Axon Registry (P18-13.008)
Benish, Sarah E. , Esper, Gregory J. , Marulanda-Londoño, Erika, Hope, Omotola , Pham, Tammy , Roe, Matthew T. , Torres, Aracelis Z. , Lien, Amanda , Kauwe, Steven, Mante, Aristotle, Lundgren, Karen B. , Schierman, Becky, Benson, Richard , Benish, Sarah, Kissela, Brett , Rosendale, Nicole , Lien, Amanda, Jones, Lyell K.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2919 Get It

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS
Harrison, Cynthia , Biery, D. N. , Zerkalenkova, Elena , Alonso‐Saladrigues, Anna , Utley, Kaylyn, Fernandes, Sneha, Carapia, Naomi Torres, Vatsayan, Anant , Pacenta, Holly , Escherich, Gabriele , Lee, Benjamin J. , Fitzjohn, Mandi R., Larson, Daniel P. , Cuevo, Raymund S., He, Rui , Reed, Kelly, Wölfl, Matthias , Raikar, Sunil S. , Savaşan, Süreyya , Puri, Latika, Gahvari, Zhubin, Talleur, Aimee C. , Abdel‐Azim, Hisham , Chamdin, Aghiad, Provost, Marlie R. M., Mezger, Kerstin, Stevens, Alexandra M. , Hsieh, Emily M. , Duffner, Ulrich, Hoang, Chloe, Davis, Kara L. , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Raikar, Sunil S , Zerkalenkova, Elena , Harrison, Cynthia , Lee, Benjamin J , Davis, Kara L , Silbert, Sara K. , Semchenkova, Alexandra , Aldoss, Ibrahim , Zhao, Liping , Rubinstein, Jeremy , Chang, Bill H , De Moerloose, Barbara , Kuo, Dennis J , Redell, Michele S. , Duployez, Nicolas , Dickens, David S. , Chaer, Firas El , Fabrizio, Vanessa A , Wang, Hao‐Wei , Yuan, Constance M. , Pan, Jing , Ghorashian, Sara , Rives, Susana , Shah, Nirali N

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4202-4202

10.1182/blood-2023-182293 Get It

Introduction: Lineage switch (LS) refers to the transformation of acute leukemia from one cell lineage to another (e.g., lymphoid (ALL) to myeloid (AML)). This rare phenomenon, distinct from treatment induced malignancy (i.e., t-AML) and mixed phenotype acute leukemia (MPAL), is increasingly being observed following cell surface antigen targeting. Given challenges in the diagnosis and treatment of LS, Project EVOLVE was developed to globally identify cases of LS following immunotherapy. Methods: A protocol and data collection form for this IRB exempt study was widely disseminated to capture deidentified LS case information across multiple centers and cancer consortia. This included collection of data from published reports of LS, with authors contacted to obtain additional information. For this analysis, LS was defined by the emergence of cell-surface markers warranting reclassification of the original leukemia as a different lineage derivation based on the immunophenotype, including cases of AML emerging alongside the original ALL. “Confirmed” LS cases included those where retention of original cytogenetic or molecular aberrations and/or the clonal immunoglobulin rearrangement patterns were verified to confirm the clonal relationship. “Suspected” LS cases included those where samples to confirm clonality marker retention could not be obtained, but the clinical presentation was consistent with LS. The term “transition” was applied when immunophenotypic shifts were transient. Cases with new cytogenetic abnormalities unrelated to the original diagnosis and compatible with t-AML were excluded. Statistical analysis was primarily descriptive. Data cut-off was July 26, 2023. Results: A total of 58 cases were identified, including 19 cases referenced in prior publications. Of the 58, 11 cases were excluded from this initial analysis, including: 4 cases of t-AML, 2 cases of T-ALL to AML, and 5 “transition” cases. Collectively, 47 cases of LS (43 “confirmed”; 4 “suspected”), spanning across 3 continents and 8 countries, were analyzed. (Fig. 1A) Cases included transition from B-ALL to AML in 36 (76.6%) and to MPAL/biphenotypic/ambiguous lineage in 11 (23.4%). Two likely had MPAL at diagnosis and a third with chronic myeloid leukemia. The median age at initial diagnosis was 8.4 years (range, 1 day-76.5 years); median age at LS presentation was 11.0 years (range 0.4-77.3 years). Twenty-three (48.9%) were male and 19 (40.4%) had prior stem cell transplant (SCT). Baseline cytogenetics showed KMT2A rearrangement in 27 (57.4%). Baseline myeloid antigen co-expression was seen in 22 of 23 patients with submitted data, but variation in degree of expression across patients and antigens was substantial. The most proximal immunotherapy prior to development of LS was CAR T-cells in 23 (48.9%) and blinatumomab in 24 (51.1%). The median time from the most proximal immunotherapy to development of LS was 1.6 months (range, 7 days-36.5 months). In 7 (29.2%) patients receiving blinatumomab, LS developed during the infusion. LS presented as isolated marrow relapse in 27 (57.4%), isolated CNS in 2 (4.3%), isolated non-CNS extramedullary disease in 3 (6.4%), combined relapse in 14 (29.8%) and unreported in 1. First line treatment for LS was chemotherapy induction in 31 (66.0%), palliative care/no therapy in 8 (17.0%), and alternative therapies in the remaining 8 (17.0%). In 35 (74.5%) patients, remission induction was the goal of first line therapy. Fifteen (31.9%) achieved a complete remission (CR) of whom 2 were treated with palliative intent. Across all patients, 8 (17.0%) are alive in remission, the longest being 4.7 years from LS diagnosis; 2 (4.3%) are alive with active LS and 37 (78.7%) died from LS, their original disease, or complications of treatment of LS (Fig 1B). For those alive in CR (n=8), 7 (87.5%) proceeded to a consolidative SCT for treatment of LS and 1 patient, an octogenarian remains in remission after AML directed therapy. Conclusions: LS is emerging as an important mechanism of immune escape following immunotherapy. Project EVOLVE provides the largest dataset of patients with LS to date. This systematic, international effort reveals substantial complexity and variability in diagnosing and managing LS. Unfortunately, outcomes following LS are grim, underscoring the critical need to identify risk factors of and optimal therapies for this leukemia transformation.
Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis
Ajufo, Helen, Harrison, Claire , Palmer, Jeanne , Buckley, Sarah , Roman‐Torres, Karisse, Rampal, Raajit K. , Bewersdorf, Jan Philipp , Palandri, Francesca , Mascarenhas, John , Gerds, Aaron T. , Kiladjian, Jean‐Jacques , Derkach, Andriy

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 3207-3207

10.1182/blood-2023-177643 Get It

Background: Pacritinib is a JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1 that demonstrated symptom benefit measured by TSS (v2.0, excluding tiredness) vs best available therapy (BAT) in PERSIST-2, which enrolled cytopenic myelofibrosis patients with platelets ≤100×10 9/L. Recent datashowed that in patients with cytopenic MF, a ≥10% reduction in spleen volume at 12 weeks is associated with improved survival in patients treated with pacritinib ( Ajufo H, et al., J Clin Oncol;2023:14(16):Suppl). Surprisingly, this association was not confirmed in patients treated with BAT (82% of whom were on ruxolitinib). The association between other important measures of clinical benefit such as symptom burden reduction and anemia improvement on survival in patients treated with pacritinib has not previously been described. Methods: Patients randomized to pacritinib 200 mg BID and to BAT on PERSIST-2 were included if they were alive and on study at the start of the week 12 efficacy assessment period. Survival was assessed by Total Symptom Score (TSS; v2.0 excluding tiredness) reduction at various thresholds (≥50%, ≥20%, ≥10%, >0%) and transfusion independence (TI) response. TI was assessed among patients who required red blood cell (RBC) transfusion at baseline (within 90 days) and was defined, for the purposes of a landmark survival analysis, as the absence of RBC transfusions over any 12-week period from first dose through week 14 (allowing for a ±2-week window around week 12). Overall survival (OS) was estimated via the K-M method following the landmark approach; survival in responders vs non-responders was compared using the log-rank test. Results: Of the 59 patients treated with pacritinib who had a reduction of TSS≥10%, the median age was 67 years, 25% had a baseline high-risk DIPSS, median platelet count was 61 x10 9/L, median hemoglobin was 9.7 g/dL, and baseline TSS was 19.1. Reduction of TSS≥10% was associated with improved OS, with 1 death among 59 responders vs 4 deaths among 30 non-responders (hazard ratio [HR]=0.12, 95% confidence interval [CI]: 0.01, 0.79] P=0.021, Fig 1a). Similar to spleen volume reduction, the association between TSS response and OS weakened at more stringent TSS response thresholds (Fig 1c, e), with the BAT arm not showing an association between TSS response and OS at any threshold. (Fig 1b, d, f). In order to assess the relationship of specific TSS domains and survival , a landmark OS analysis was performed based on ≥20% reduction in physical function scores (sum of ‘tiredness’ and 'inactivity'), spleen-related symptom scores (sum of 'abdominal discomfort', ‘early satiety’, and 'left rib pain'), and cytokine-related symptom scores (sum of 'itching', ‘night sweats’, and ‘bone pain‘). For cytokine-related symptoms, the number of deaths in PAC responders was significantly different compared to non-responders, with 0 deaths among 35 responders vs 2 among 15 non-responders ( P=0.0325). Conversely the deaths among responders (2/22) vs non-responders (2/20) were not significantly different in the BAT arm. For the physical function and spleen-related symptom subscales, no significant differences between PAC responders and non-responders was observed (HR=0.60; 95% CI [0.05, 6.74] P=0.679) and (HR=0.26; 95% CI 0.02, 2.93, P=0.2435) respectively. Among 36 patients on PAC who received RBC transfusions at baseline, 7 achieved TI over at least a 12-week period up to the time of the landmark analysis. There were no deaths among TI responders compared to 2 (6.9%) among TI non-responders. There were too few TI responders on BAT (only 2 out of 38) to assess the impact on survival. Conclusion: In cytopenic myelofibrosis patients enrolled in PERSIST-2, having a reduction of TSS≥10% on full-dose PAC was associated with OS benefit - a finding that has not been noted with other JAK inhibitors to date. By contrast, this association was not found with BAT, (82% of these patients received ruxolitinib). Thus, reductions in TSS in patients treated with PAC were associated with an OS benefit. It is possible that pacritinib, with its distinctive mechanism of action, may offer a unique survival advantage for MF patients with moderate or severe thrombocytopenia, and further studies are required to understand the potential mechanisms of these distinct clinical observations. Study funded by CTI BioPharma Corp., a Sobi company.
Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells
Bhagwat, Anand , Torres, Leonel , Shestova, Olga, Shestov, Maksim, Luger, Selina M. , Loren, Alison W. , Martin, Mary Ellen , Perl, Alexander E. , Stadtmauer, Edward A. , Mangan, James K. , Brogdon, Jennifer L. , Fraietta, Joseph A. , Hwang, Wei‐Ting , June, Carl H. , Frey, Noelle V. , Hexner, Elizabeth O. , McCurdy, Shannon , Siegel, Donald L , Kenderian, Saad S. , Porter, David , Gill, Saar

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 217-217

10.1182/blood-2023-182104 Get It

Background: Chimeric antigen receptor (CAR) T cells have repeatedly demonstrated capacity to induce high rates of response and durable remissions for B cell cancers. In contrast, CAR T cells for the treatment of acute myeloid leukemia (AML) have not yet achieved this impact. We previously demonstrated that CD123 is expressed on AML blasts at high frequency, thus making it an attractive target antigen for AML-directed CAR T cells. Methods and Results: We conducted a pilot study of CD123-directed CAR T cells (CART-123) in adults with relapsed or refractory AML. The primary objective was safety with a secondary objective of anti-leukemia efficacy. Twenty-two subjects were screened, and 20 were eligible for the trial. Fludarabine and cyclophosphamide were used for lymphodepletion (LD). Twelve subjects were infused with CART-123. There were two treatment-related deaths due to cytokine release syndrome (CRS) and infection. Four subjects (33%) achieved complete response with incomplete count recovery (CRi), three subjects had progressive disease, and five had stable disease. Of the four who achieved CRi, one subject remains alive in remission after a relapse and subsequent consolidative hematopoietic stem cell transplant (HSCT). One other subject is alive after HSCT following CART-123 failure. There was evidence of CAR T cell expansion and ten subjects (83%) experienced clinical CRS ranging from Grade I to Grade V. There was no neurotoxicity. To address the apparent paradox of high rates of CART-123 bioactivity (clinical CRS and in vivo expansion) co-occurring with low rates of response, we hypothesized that cytokines produced during CRS may undermine the anti-AML effect of CART cells. We obtained serum drawn from trial subjects at baseline (prior to LD chemotherapy) or during CRS. Serum drawn during CRS promotes primary AML survival in cell culture, while matched baseline serum from the same subjects does not. Individual cytokines secreted during CRS that signal through receptors expressed on myeloid progenitors (such as GM-CSF and Flt3 ligand) reproduced this survival advantage in primary AML blasts when tested at physiologically relevant levels. In contrast, these cytokines did not produce a pro-survival effect in primary patient B-ALL blasts. Crucially, candidate myeloid-acting cytokines, as well as serum drawn during the peak of clinical CRS, promoted resistance of AML to killing by CART-123 in vitro. Using scRNAseq of bone marrow aspirates from subjects on this clinical trial, we found that GM-CSF and FLT3L were most frequently expressed by CD4+ T cells. Exposure of primary AML samples to CRS cytokines led to upregulation of signaling (e.g. JAK/STAT5) and pro-survival pathways. In previous work in B-ALL, we showed that relative resistance to killing can translate to a functional deficit in CART-19 due to development of exhaustion in the CART cells. We similarly find that that exposure to GM-CSF reduces AML blast sensitivity to CART-123, and that the persistence of antigen leads to exhaustion in CART cells (Figure 1). Specifically, co-incubation of CART-123 cells and cytokine-exposed primary AML blasts leads to increased populations of PD-1+/CD39+/CTLA4+/LAG3+ CAR T cells, consistent with an exhaustion phenotype. Finally, we found that anti-apoptotic effects of cytokines can be prevented, and CART-123 killing of AML can be restored, via ruxolitinib blockade of JAK/STAT signaling in both in vitro and in vivo settings. Significance: Our work reveals CRS as active in undermining CART-123 lethality first by promoting survival of AML, and subsequently by exhausting CAR T cells. This is in stark contrast to its role in lymphoid malignancies and underscores biological differences in myeloid versus lymphoid neoplasms. These results highlight a need to tailor therapy to limit cytokine effects on AML blasts to improve outcomes with AML-directed CAR T cell therapy.